A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2018-02-13
Target enrollment:
Participant gender:
Summary
The trial's objective is to evaluate the immunogenicity of repeated single doses of
dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1
diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon
and GlucaGen.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207